A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus [Randomizovane, dvojite zaslepene, placebem kontrolovane klinicke hodnoceni faze 3 s paralelnimi skupinami hodnotici ucinnost a bezpecnostRanolazinu pridaneho k Metforminu u pacientu s diabetes mellitus 2. typu]

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus [Randomizovane, dvojite zaslepene, placebem kontrolovane klinicke hodnoceni faze 3 s paralelnimi skupinami hodnotici ucinnost a bezpecnostRanolazinu pridaneho k Metforminu u pacientu s diabetes mellitus 2. typu]

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Ranolazine (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2013 Top-line results are expected in late 2013 according to a Gilead Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top